Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia[S]

In an attempt to understand the applicability of various animal models to dyslipidemia in humans and to identify improved preclinical models for target discovery and validation for dyslipidemia, we measured comprehensive plasma lipid profiles in 24 models. These included five mouse strains, six other nonprimate species, and four nonhuman primate (NHP) species, and both healthy animals and animals with metabolic disorders. Dyslipidemic humans were assessed by the same measures. Plasma lipoprotein profiles, eight major plasma lipid fractions, and FA compositions within these lipid fractions were compared both qualitatively and quantitatively across the species. Given the importance of statins in decreasing plasma low-density lipoprotein cholesterol for treatment of dyslipidemia in humans, the responses of these measures to simvastatin treatment were also assessed for each species and compared with dyslipidemic humans. NHPs, followed by dog, were the models that demonstrated closest overall match to dyslipidemic humans. For the subset of the dyslipidemic population with high plasma triglyceride levels, the data also pointed to hamster and db/db mouse as representative models for practical use in target validation. Most traditional models, including rabbit, Zucker diabetic fatty rat, and the majority of mouse models, did not demonstrate overall similarity to dyslipidemic humans in this study.

[1]  C. Beals,et al.  The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[2]  Abhinav Goyal,et al.  The Role of C-Reactive Protein as a Risk Predictor of Coronary Atherosclerosis: Implications from the JUPITER Trial , 2011, Current atherosclerosis reports.

[3]  A. Lichtenstein,et al.  Use of hamster as a model to study diet-induced atherosclerosis , 2010, Nutrition & metabolism.

[4]  Eoin Fahy,et al.  Lipidomics reveals a remarkable diversity of lipids in human plasma1[S] , 2010, Journal of Lipid Research.

[5]  E. Falk,et al.  Atherosclerotic lesions in mouse and man: is it the same disease? , 2010, Current opinion in lipidology.

[6]  R. Srivastava,et al.  Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster , 2010, Molecular and Cellular Biochemistry.

[7]  Kim Ekroos,et al.  Lipidomics: A Tool for Studies of Atherosclerosis , 2010, Current atherosclerosis reports.

[8]  A. Kontush,et al.  Lipidomics as a Tool for the Study of Lipoprotein Metabolism , 2010, Current atherosclerosis reports.

[9]  A. Goyal,et al.  Should We Measure C‐reactive Protein on Earth or Just on JUPITER? , 2010, Clinical cardiology.

[10]  Shu-Hua Tai,et al.  A systematic review and meta‐analysis on the therapeutic equivalence of statins , 2010, Journal of clinical pharmacy and therapeutics.

[11]  J. Genest C-reactive protein: risk factor, biomarker and/or therapeutic target? , 2010, The Canadian journal of cardiology.

[12]  J. Condra,et al.  A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake , 2010, The Journal of Biological Chemistry.

[13]  Alexander Tsertsvadze,et al.  Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia , 2009, Annals of Internal Medicine.

[14]  J. Tomassini,et al.  Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia , 2009, Diabetes, obesity & metabolism.

[15]  G. Lip,et al.  Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy , 2009, Vascular health and risk management.

[16]  S. Tardif,et al.  Characterization of Obese Phenotypes in a Small Nonhuman Primate, the Common Marmoset (Callithrix jacchus) , 2009, Obesity.

[17]  J. Kastelein,et al.  Triglycerides and Cardiovascular Risk , 2009, Current cardiology reviews.

[18]  A. Remaley,et al.  Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease. , 2009, Current opinion in endocrinology, diabetes, and obesity.

[19]  P. Alagona Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. , 2009, The American journal of managed care.

[20]  H. Vinters,et al.  Vulnerable Plaque in a Swine Model of Carotid Atherosclerosis , 2009, American Journal of Neuroradiology.

[21]  R. Califf,et al.  Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. , 2008, American heart journal.

[22]  I. Kola,et al.  The State of Innovation in Drug Development , 2008, Clinical pharmacology and therapeutics.

[23]  Cholesterol Treatment Trialists' Collaborators Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis , 2008, The Lancet.

[24]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[25]  Michelle M Wiest,et al.  A lipidomic analysis of nonalcoholic fatty liver disease , 2007, Hepatology.

[26]  M. Jauhiainen,et al.  Important Role for Bone Marrow–Derived Cholesteryl Ester Transfer Protein in Lipoprotein Cholesterol Redistribution and Atherosclerotic Lesion Development in LDL Receptor Knockout Mice , 2007, Circulation research.

[27]  H. Oliveira,et al.  REGULATION OF HEPATIC CHOLESTEROL METABOLISM IN CETP+/–/LDLr+/– MICE BY CHOLESTEROL FEEDING AND BY DRUGS (CHOLESTYRAMINE AND LOVASTATIN) THAT LOWER PLASMA CHOLESTEROL , 2006, Clinical and experimental pharmacology & physiology.

[28]  S. Proctor,et al.  Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. , 2006, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[29]  R. Knopp,et al.  Management of dyslipidaemias , 2006, Heart.

[30]  Christopher P Cannon,et al.  Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.

[31]  P. Nguyen,et al.  Fenofibrate lowers lipid parameters in obese dogs. , 2006, The Journal of nutrition.

[32]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[33]  Robert V Farese,et al.  Plasma Cholesteryl Esters Provided by Lecithin:Cholesterol Acyltransferase and Acyl-Coenzyme A:Cholesterol Acyltransferase 2 Have Opposite Atherosclerotic Potential , 2004, Circulation research.

[34]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[35]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[36]  L. Rogers,et al.  Saliva sampling to assess cortisol levels in unrestrained common marmosets and the effect of behavioral stress , 2004, American journal of primatology.

[37]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[38]  M. Sturek,et al.  Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile. , 2002, Journal of lipid research.

[39]  S. Yusuf,et al.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.

[40]  Chunjiang Yu,et al.  Roles of acyl-coenzyme A : cholesterol acyltransferase-1 and -2 , 2001, Current opinion in lipidology.

[41]  K. Tsutsumi,et al.  The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals. , 2001, Biological & pharmaceutical bulletin.

[42]  H. Princen,et al.  Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? , 1998, Atherosclerosis.

[43]  P. Gambert,et al.  Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species. Relation to atherogenesis susceptibility. , 1998, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[44]  T. Yoshino,et al.  Systemic atherosclerosis in dogs: histopathological and immunohistochemical studies of atherosclerotic lesions. , 1998, Journal of comparative pathology.

[45]  J. Cho,et al.  A peptide from hog plasma that inhibits human cholesteryl ester transfer protein. , 1998, Biochimica et biophysica acta.

[46]  S. Yamamoto,et al.  Development of monkey C-reactive protein (CRP) assay methods. , 1998, Veterinary immunology and immunopathology.

[47]  K. Suckling,et al.  SR-12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis. , 1997, Atherosclerosis.

[48]  A. Tall,et al.  Human Cholesteryl Ester Transfer Protein Gene Proximal Promoter Contains Dietary Cholesterol Positive Responsive Elements and Mediates Expression in Small Intestine and Periphery While Predominant Liver and Spleen Expression Is Controlled by 5′-distal Sequences , 1996, The Journal of Biological Chemistry.

[49]  R. Virmani,et al.  Hypercholesterolemia in the rabbit induced by feeding graded amounts of low-level cholesterol. Methodological considerations regarding individual variability in response to dietary cholesterol and development of lesion type. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[50]  W. Harris n-3 fatty acids and lipoproteins: Comparison of results from human and animal studies , 1996, Lipids.

[51]  R. Hammer,et al.  Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.

[52]  J. Borensztajn,et al.  Hepatic lipase function and the accumulation of beta-very-low-density lipoproteins in the plasma of cholesterol-fed rabbits. , 1993, Biochemical Journal.

[53]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[54]  E. Rubin,et al.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.

[55]  A. Tall,et al.  Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. , 1992, The Journal of clinical investigation.

[56]  H. Pownall,et al.  Comparative specificity of plasma lecithin: Cholesterol acyltransferase from ten animal species , 1991, Lipids.

[57]  J. Isner,et al.  Atherosclerotic Yucatan microswine: an animal model with high-grade, fibrocalcific, nonfatty lesions suitable for testing catheter-based interventions. , 1990, American heart journal.

[58]  A. Tall,et al.  Atherogenic diet increases cholesteryl ester transfer protein messenger RNA levels in rabbit liver. , 1990, The Journal of clinical investigation.

[59]  P. Barter,et al.  The rabbit as an animal model of hepatic lipase deficiency. , 1989, Biochimica et biophysica acta.

[60]  D. Bassett,et al.  Cholesterol kinetic analysis in normal and cholesterol-fed rabbits; effects of saturated versus polyunsaturated fat and of cholestyramine. , 1975, The Journal of nutrition.

[61]  W. Lands,et al.  Specificity of acyl-CoA:phospholipid acyltransferases: solvent and temperature effects. , 1968, Journal of lipid research.

[62]  W. Lands,et al.  Metabolism of glycerolipids. III. Reactivity of various acyl esters of coenzyme A with alpha'-acylglycerophosphorylcholine, and positional specificities in lecithin synthesis. , 1963, The Journal of biological chemistry.

[63]  W. Lands Metabolism of glycerolipids. 2. The enzymatic acylation of lysolecithin. , 1960, The Journal of biological chemistry.

[64]  D. Moher,et al.  Systematic review: comparative effectiveness and harms of combinations of lipid-modifying agents and high-dose statin monotherapy , 2009 .

[65]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[66]  W. Howard Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .

[67]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[68]  P. Hart,et al.  Metabolism of Glycerolipids , 2003 .

[69]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[70]  S. Crispin,et al.  Plasma lipoprotein lipids in five different breeds of dogs. , 1993, Research in veterinary science.

[71]  H. Gewurz,et al.  Radioimmunoassay of human C-reactive protein and levels in normal sera. , 1976, The Journal of laboratory and clinical medicine.